Therefore, in this study we sought to explore the utility of HER1-targeting 86Y-labeled cetuximab and panitumumab for PET imaging of MM, to assess HER1 status, and as a means to select and screen subjects for HER1-targeted radioimmunotherapy (RIT) with radionuclides such as 90Y for larger tumors or α-emitting radionuclides such as 212Pb for micrometastatic disease [28], [29], [30], [31]. Here, EGFR is linked to Miyoshi myopathy.